Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Multifocal motor neuropathy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Baxalta; Baxter Corporation

    • Most Recent Events

    • 22 Jun 2021 Results of a post hoc analysis assessing how grip strength (GS) responded to serum immunoglobulin G (IgG) trough alterations in multifocal motor neuropathy presented at the 7th Congress of the European Academy of Neurology
    • 27 Apr 2012 Primary endpoint 'Strength' has been met.
    • 27 Apr 2012 Primary endpoint 'UK-Neurological-Disability-Scale' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top